Monocyte function and trafficking in cardiovascular disease

Thrombosis and Haemostasis

Volumn 108, Issue 5, 2012, Pages 804-811

  Pardali, Evangelia ^a   Waltenberger, Johannes ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Atherosclerosis; Cardiovascular disease; Monocytes; Myocardial infarction

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; FLUORODEOXYGLUCOSE F 18; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CELL FUNCTION; CELL INFILTRATION; CELL MIGRATION; CELL SUBPOPULATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DENDRITIC CELL; DIABETES MELLITUS; DISEASE MARKER; HEART INFARCTION; HUMAN; INFLAMMATION; MACROPHAGE; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MONOCYTE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE REPAIR; VASCULAR SURGERY;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CELL MOVEMENT; HUMANS; MICE; MONOCYTES; NEOVASCULARIZATION, PHYSIOLOGIC; WOUND HEALING;

EID: 84869992773     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-04-0276     Document Type: Article

References (97)

1. Serbina NV and Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006; 7: 311-317.
2. Tsou CL, Peters W, Si Y, et al. Critical roles for CCR2 and MCP-3 in monocyte mobili zati o n from b on e marrow and recruitment to inflammatory sites. J Clin In -vest 2007; 117: 902-909.
3. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007; 317: 666-670.
4. Auffray C, Fogg DK, Narni-Mancinelli E, et al. CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. J Exp Med 2009; 206: 595-606.
5. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27: 669-692.
6. van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. J Exp Med 1968; 128: 415-435.
7. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325: 612-616.
8. Liu K, Waskow C, Liu X, et al. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol 2007; 8: 578-583.
9. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011; 11: 762-774.
10. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
11. Heine GH, Ortiz A, Massy ZA, et al. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 2012; 8: 362-369.
12. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007; 81: 584-592.
13. Ancuta P, Liu KY, Misra V, et al. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics 2009; 10: 403.
14. Ancuta P, Rao R, Moses A, et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197: 1701-1707.
15. Weber C, Belge KU, von Hundelshausen P, et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 200; 67: 699-704.
16. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-3542.
17. Czepluch FS, Olieslagers S, van Hulten R, et al. VEGF-A-induced chemotaxis of CD16+ monocytes is decreased secondary to lower VEGFR-1 expression. Atherosclerosis 2011; 215: 331-338.
18. Szaflarska A, Baj-Krzyworzeka M, Siedlar M, et al. Antitumor response of CD14+/CD16+ monocyte subpopulation. Exp Hematol 2004; 32: 748-755.
19. Zhao C, Zhang H, Wong WC, et al. Identification of novel functional differences in monocyte subsets using proteomic and transcriptomic methods. J Proteome Res 2009; 8: 4028-4038.
20. Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33: 375-386.
21. Zawada AM, Rogacev KS, Rotter B, et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118: e50-61.
22. Landsman L, Bar-On L, Zernecke A, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009; 113: 963-972.
23. Krutzik SR, Tan B, Li H, et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med 2005; 11: 653-660.
24. Randolph GJ, Sanchez-Schmitz G, Liebman RM et al. The CD16(+) (Fcgamma-R3(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 2002; 196: 517-527.
25. Elsheikh E, Uzunel M, He Z, et al. Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. Blood 2005; 106: 2347-2355.
26. Coffelt SB, Lewis CE, Naldini L, et al. Elusive identities and overlapping pheno-types of proangiogenic myeloid cells in tumors. Am J Pathol 2010; 176: 1564-1576.
27. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
28. Kuziel WA, Morgan SJ, Dawson TC, et al. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci USA 1997; 94: 12053-12058.
29. Mahad DJ, Trebst C, Kivisakk P, et al. Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern 3 multiple sclerosis lesions. J Neuropathol Exp Neurol 2004; 63: 262-273.
30. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194.
31. Gordon S and Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
32. Qu C, Edwards EW, Tacke F, et al. Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med 2004; 200: 1231-1241.
33. Sunderkotter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004; 172: 4410-4417.
34. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-3047.
35. Carmeliet P and Luttun A. The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis. Thromb Haemost 2001; 86: 289-297.
36. Heil M, Ziegelhoeffer T, Pipp F, et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 2002; 283: H2411-H2419.
37. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001; 49: 554-560.
38. Waltenberger J, Kranz A, Beyer M. Neovascularization in the human heart is associated with expression of VEGF-A and its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2). Results from cardiomyopexy in ischemic cardiomyopathy. Angio-genesis 1999; 3: 345-351.
39. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 2000; 102: 185-190.
40. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and in-termolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943.
41. Waltenberger J. VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. Biochem Soc Trans 2009; 37: 1167-1170.
42. Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005; 174: 215-222.
43. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-in-hibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463-475.
44. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26: 25-35.
45. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of en-dothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 1584-1595.
46. Hristov M, Gumbel D, Lutgens E, et al. Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury. Circulation 2010; 121: 315-324.
47. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells"are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164-1169.
48. Tchaikovski V, Fellbrich G, Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol 2008; 28: 322-328.
49. Pipp F, Heil M, Issbrucker K, et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 2003: 92: 378-385.
50. Scholz D, Elsaesser H, Sauer A, et al. Bone marrow transplantation abolishes inhibition of arteriogenesis in placenta growth factor (PlGF) -/- mice. J Mol Cell Cardiol 2003; 35: 177-184.
51. Beck H, Raab S, Copanaki E, et al. VEGFR-1 signaling regulates the homing of bone marrow-derived cells in a mouse stroke model. J Neuropathol Exp Neurol 2010; 69: 168-175.
52. Kami J, Muranaka K, Yanagi Y, et al. Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase. Jpn J Oph-thalmol 2008; 52: 91-98.
53. Murakami M, Iwai S, Hiratsuka S, et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 2006; 108: 1849-1856.
54. Zhao Q, Egashira K, Hiasa K, et al. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arte-rioscler Thromb Vasc Biol 2004; 24: 2284-2289.
55. Voo S, Eggermann J, Dunaeva M, et al. Enhanced functional response of CD133+ circulating progenitor cells in patients early after acute myocardial infarction. Eur Heart J 2008; 29: 241-250.
56. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009; 102: 240-247.
57. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
58. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholeste-rolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
59. Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1424-1432.
60. Tsujioka H, Imanishi T, Ikejima H, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009; 54: 130-138.
61. Tsujioka H, Imanishi T, Ikejima H, et al. Post-reperfusion enhancement of CD14(+)CD16(-) monocytes and microvascular obstruction in ST-segment elevation acute myocardial infarction. Circ J 2010; 74: 1175-1182.
62. Hristov M, Leyendecker T, Schuhmann C, et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.
63. Hristov M, Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb Haemost 2011; 106: 757-762.
64. Lee WW, Marinelli B, van der Laan AM, et al. PET/MRI of inflammation in myo-cardial infarction. J Am Coll Cardiol 2012; 59: 153-163.
65. Leuschner F, Rauch PJ, Ueno T, et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med 2012; 209: 123-137.
66. Libby P. The interface of atherosclerosis and thrombosis: basic mechanisms. Vasc Med 1998; 3: 225-229.
67. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-358.
68. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-325.
69. Ross R, Faggiotto A, Bowen-Pope D et al. The role of endothelial injury and platelet and macrophage interactions in atherosclerosis. Circulation 1984; 70:3 77-82.
70. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150: 1687-1699.
71. Rajavashisth T, Qiao JH, Tripathi S, et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. J Clin Invest 1998; 101: 2702-2710.
72. Robbins CS, Chudnovskiy A, Rauch PJ, et al. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation 2012; 125: 364-374.
73. Combadiere C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008; 117: 1649-1657.
74. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111: 333-340.
75. Saederup N, Chan L, Lira SA et al. Fractalkine deficiency markedly reduces mac-rophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008; 117: 1642-1648.
76. Leuschner F, Dutta P, Gorbatov R, et al. Thera peuticsi RNA silencingi n i n f la mmatory monocytes in mice. Nat Biotechnol 2011; 29: 1005-1010.
77. Tchaikovski V, Olieslagers S, Bohmer FD, Waltenberger J. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation 2009; 120: 150-159.
78. Dunaeva M, Voo S, van Oosterhoud C, Waltenberger J. Sonic hedgehog is a potent chemoattractant for human monocytes: diabetes mellitus inhibits Sonic hedgehog-induced monocyte chemotaxis. Basic Res Cardiol 2010; 105: 61-71.
79. Olieslagers S, Pardali E, Tchaikovski V, et al. TGF-β1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus. Cardiovasc Res 2011; 91: 510-518.
80. Czepluch FS, Bergler A, Waltenberger J. Hypercholesterolaemia impairs mono-cyte function in CAD patients. J Intern Med 2007; 261: 201-204.
81. Stadler N, Eggermann J, Voo S, et al. Smoking-induced monocyte dysfunction is reversed by vitamin C supplementation in vivo. Arterioscler Thromb Vasc Biol 2007; 27: 120-126.
82. Berg KE, Ljungcrantz I, Andersson L, et al. Elevated CD14++CD16- monocytes predict cardiovascular events. Circ Cardiovasc Genet 2012; 5: 122-131.
83. Heine GH, Ulrich C, Seibert E, et al. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008; 73: 622-629.
84. Rogacev KS, Seiler S, Zawada AM, et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32: 84-92.
85. Urra X, Villamor N, Amaro S, et al. Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab 2009; 29: 994-1002.
86. Libby P, Nahrendorf M, Weissleder R. Molecular imaging of atherosclerosis: a progress report. Tex Heart Inst J 2010; 37: 324-327.
87. Devaraj NK, Keliher EJ, Thurber GM, et al. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem 2009; 20: 397-401.
88. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008; 117: 379-387.
89. Lipinski MJ, Frias JC, Amirbekian V, et al. Macrophage-specific lipid-based nano-particles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging 2009; 2: 637-647.
90. Nahrendorf M, Sosnovik D, Chen JW, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvas-ively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008; 117: 1153-1160.
91. Trivedi RA, Mallawarachi C, JM UK-I, Graves MJ, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macro-phages. Arterioscler Thromb Vasc Biol 2006; 26: 1601-1606.
92. Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging 2010; 3: 388-397.
93. Rudd JH, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol 2010; 55: 2527-2535.
94. Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009; 50: 563-568.
95. Montet-Abou K, Daire JL, Hyacinthe JN, et al. In vivo labelling of resting mono-cytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. Eur Heart J 2010; 31: 1410-1420.
96. Oude Engberink RD, van der Pol SM, Dopp EA, et al. Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. Radiology 2007; 243: 467-474.
97. Swirski FK, Wildgruber M, Ueno T, et al. Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice. J Clin Invest 2010; 120: 2627-2634.